MTOR and hepatocellular carcinoma: Similar to previous reports, Sirolimus did not significantly inhibit proliferation and activation of the AKT–mTOR pathway in MDA–MB–231 and HCC–1937 cells (Figure 5G,H, see full western blot images and histogram in Supplementary Materials).